On October 21, Dean Diagnosis held an investor relations event to report on the business situation and AI strategy overview for the first three quarters. At the operating level, the company achieved operating income of 7.409 billion yuan in the first three quarters, down 2.07% year on year; net profit to mother of 482 million yuan, up 750.28% year on year; deducted non-net profit of 418 million yuan, up 1074.80% year on year; and operating cash flow of 824 million yuan, which remained high over the years. Looking at a single quarter, revenue for the third quarter was 2,635 billion yuan, up 0.23% year on year, and net profit to mother was 250 million yuan, up 438.03% year on year. The trend of improving revenue from quarter to quarter is clear. By business, revenue from the diagnostic services business was 2,645 billion yuan, up 0.87% year on year, showing a quarterly improvement trend. The cumulative growth rate changed from negative to positive; channel product business revenue was 4.710 billion yuan, down 4.47% year on year, and the decline narrowed; revenue from the proprietary products business was 300 million yuan, up 5.70% year on year, continuing to grow. In terms of AI strategy, in June 2025, the company first released the AI three-year strategic plan, clarifying the AI strategic position of “deepening the medical and health scenario, using 'AI+ data' as the engine to lead the intelligent future of industrial ecology”, and clarifying that the Group's overall AI business performance contribution will grow 100% every year for the next 3 years. Relying on the national network, the company has accumulated 22PB of multi-omics and multi-modal data, adding about 1.6 PB of data every year; it has now cleaned and treated 6PB+ high-quality data. The company has two core self-developed large models: the “Enlightenment Micro” multi-modal large model and the “Smart Eye” multi-modal large model, which focuses on the field of pathology, and has launched a “3+1” product matrix for different customer groups.

On October 21, Dean Diagnosis held an investor relations event to report on the business situation and AI strategy overview for the first three quarters. At the operating level, the company achieved operating income of 7.409 billion yuan in the first three quarters, down 2.07% year on year; net profit to mother of 482 million yuan, up 750.28% year on year; deducted non-net profit of 418 million yuan, up 1074.80% year on year; and operating cash flow of 824 million yuan, which remained high over the years. Looking at a single quarter, revenue for the third quarter was 2,635 billion yuan, up 0.23% year on year, and net profit to mother was 250 million yuan, up 438.03% year on year. The trend of improving revenue from quarter to quarter is clear. By business, revenue from the diagnostic services business was 2,645 billion yuan, up 0.87% year on year, showing a quarterly improvement trend. The cumulative growth rate changed from negative to positive; channel product business revenue was 4.710 billion yuan, down 4.47% year on year, and the decline narrowed; revenue from the proprietary products business was 300 million yuan, up 5.70% year on year, continuing to grow. In terms of AI strategy, in June 2025, the company first released the AI three-year strategic plan, clarifying the AI strategic position of “deepening the medical and health scenario, using 'AI+ data' as the engine to lead the intelligent future of industrial ecology”, and clarifying that the Group's overall AI business performance contribution will grow 100% every year for the next 3 years. Relying on the national network, the company has accumulated 22PB of multi-omics and multi-modal data, adding about 1.6 PB of data every year; it has now cleaned and treated 6PB+ high-quality data. The company has two core self-developed large models: the “Enlightenment Micro” multi-modal large model and the “Smart Eye” multi-modal large model, which focuses on the field of pathology, and has launched a “3+1” product matrix for different customer groups.